Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

ClinicalTrials.gov ID: NCT06577090

Public ClinicalTrials.gov record NCT06577090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Study identification

NCT ID: NCT06577090
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Skye Bioscience, Inc.; Industry
Enrollment: 136 participants

Conditions and interventions

Conditions

Obesity

Interventions

Nimacimab injection Biological
Nimacimab placebo injection Biological
semaglutide injection Combination Product
Nimacimab 300 mg injection Biological

Biological · Combination Product

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 22, 2024 (Actual)
Primary completion: Nov 20, 2026 (Estimated)
Completion: Feb 28, 2027 (Estimated)
Last update posted: Jan 14, 2026

2024 – 2027

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Pinnacle Research Group	Anniston	Alabama	36207	—
Diablo Clinical Research, Inc.	Walnut Creek	California	94598	—
Chase Medical Research, LLC	Waterbury	Connecticut	06708	—
ACCEL Research Sites	Atlanta	Georgia	30342	—
Center for Advanced Research & Education	Gainesville	Georgia	30501	—
L-MARC Research Center	Louisville	Kentucky	40213	—
Be Well Clinical Studies	Lincoln	Nebraska	68516	—
Palm Research Center	Las Vegas	Nevada	89148	—
ActivMed Practices & Research	Portsmouth	New Hampshire	03801	—
Weill Cornell Medicine	New York	New York	11375	—
Accellacare of Wilmington	Wilmington	North Carolina	28401	—
Lillestol Research, LLC	Fargo	North Dakota	58104	—
Velocity Clinical Research, Dallas	Dallas	Texas	75230	—
Be Well Clinical Studies	Round Rock	Texas	78681	—
Charlottesville Medical Research	Charlottesville	Virginia	22911	—
Rainier Clinical Research Center	Renton	Washington	98057	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06577090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06577090 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →